Compare CDXS & CNXU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CDXS | CNXU |
|---|---|---|
| Founded | 2002 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Industrial Specialties |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 256.3M | 282.3M |
| IPO Year | 2008 | N/A |
| Metric | CDXS | CNXU |
|---|---|---|
| Price | $1.49 | $8.52 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 796.1K | 113.0K |
| Earning Date | 05-07-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.82 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $138,590,000.00 | N/A |
| Revenue This Year | $7.73 | N/A |
| Revenue Next Year | $14.24 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 32.30 | N/A |
| 52 Week Low | $0.96 | $8.14 |
| 52 Week High | $3.87 | $13.66 |
| Indicator | CDXS | CNXU |
|---|---|---|
| Relative Strength Index (RSI) | 23.79 | 36.33 |
| Support Level | $1.10 | N/A |
| Resistance Level | $1.86 | $11.45 |
| Average True Range (ATR) | 0.15 | 1.48 |
| MACD | -0.07 | -0.10 |
| Stochastic Oscillator | 5.33 | 6.52 |
Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.
Conexeu Sciences Inc is an early-stage medical technology company. The company develops and supplies collagen-based technologies that helps doctors and patients regenerate tissue naturally, safely, and effectively. The company is focused on developing regenerative biomaterials that address relative needs in wound care, dentistry, and aesthetics. The company seek to provide physicians with device-based solutions that improve healing, restore soft tissue, and enhance patient outcomes across multiple clinical settings. The company focuses durable, and growing addressable markets in regenerative aesthetics, wound care, 3D-printed tissue structures, veterinary wound repair, and dental soft-tissue regeneration.